U.S. markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.48-0.10 (-0.95%)
At close: 4:00PM EDT
Sign in to post a message.
  • m
    muck
    The Potential Role of p38 Inhibition in the Treatment of COVID-19

    Several lines of preclinical and clinical evidence indicate that activation of the p38 mitogen-activated protein kinase (MAPK) significantly contributes to the pathogenesis of coronavirus infections including COVID-19. p38 MAPK is well known as an important mediator of acute response to stress, including acute inflammation.

    In two clinical studies reported in the literature, an oral dose of 15 mg twice per day of losmapimod in older individuals restored the normal immune response to a viral antigen challenge and demonstrated resolution of acute inflammation, a relevant observation because the majority of severe and fatal cases of COVID-19 occur in older individuals. Additionally, in prior human clinical trials predominantly in chronic inflammatory conditions, losmapimod had an immediate effect on a number of inflammatory biomarkers that have been associated with poor prognosis in COVID-19, including C-reactive protein (CRP) and interleukin-6 (IL-6). In previous trials in more than 3,600 subjects, losmapimod exhibited favorable safety and tolerability not significantly different from placebo. These trials have also indicated that losmapimod had good exposure after oral dosing and robust target engagement.

    The Company believes that losmapimod has the potential to treat COVID-19 by reducing the acute exaggerated pro-inflammatory responses to SARS-CoV-1 infection and restoring the antigen-specific immune responses needed for clearance of SARS-CoV-2, potentially leading to improved clinical outcomes. Additionally, p38 inhibition has been demonstrated to reduce angiotensin II (Ang II)-induced endothelial and organ damage in several experimental models and may address the renin-angiotensin system imbalance that is believed to contribute to key morbidities in COVID-19 patients.
  • V
    Venom Snake
    low volume still goes down... today is the 4th day
  • J
    Justin
    Alright guys let's start a discussion. FULC dropped 45% today.
  • R
    Robert
    I love these fresh stocks so much movement in so little time. plus this one should be at $19 soon.
  • A
    AB
    is it good buy ?
  • J
    Jonathan
    I picked the wrong entry point...
  • A
    Alex
    I just got in at 7.65..... am I catching a falling knife? I feel like I want to just hold this for a month or so. I think a $10 price does not seem unrealistic....
  • J
    Jonathan
    I'm not heavily invested got in at the wrong entry point though...
  • V
    Venom Snake
    @Jonathan i hope we see an after hours run!
  • M
    Marco
    Repported Q2 EPS of ($0.66), $0.12 better than the analyst estimate of ($0.78). So i don't know why this big drop. The 1 year target is 26.40 and analists suggest its a strong buy.
  • V
    Venom Snake
    not looking good, my new average is 7.53 but with new low today @7.31 i wonder if i this is enough
  • V
    Venom Snake
    sank on 54k volume, wow
  • M
    Marco
    Proof of clinical trial! To the Moon FDA approval
    Bullish
  • d
    david
    Whats the word on the phase three covid treatment?
    Bullish
  • R
    Rocnon
    if the sell-off continues tomorrow for a drop into the 6,s i will be a buyer. this already seems over sold to me. I'm thinking preliminary trials data does not justify the kind of bloodletting we are seeing here.
  • E
    Elijah True
    how was earnings
  • Y
    Yahoo Finance Insights
    FULC is up 19.88% to 12.48
  • Y
    Yahoo Finance Insights
    FULC is up 19.88% to 12.48
  • E
    Elegance Trader
    Can someone answer this please: FULC announced share offering at $11 and today it went up to $13 on the market. How does that work? Not that I am not happy about it. Thanks
  • V
    Venom Snake
    low of the day 7.61 yesterday's low of the day 7.65, not much different